Search global stocks & ETFs...Ctrl K

Learn Mode

BMY - Bristol-Myers Squibb Co

310

$56.16

-$0.09 (-0.160%)

At market close

$56.12

-$0.04 (-0.067%)

After Hours 5/8/26, 10:21 PM

Score

3.73/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

BMY

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$114.68B

Industry

Pharmaceuticals

EPS (TTM)

$2.91

P/E (TTM)

19.20

Div & Yield

$2.52 (4.49%)

FCF Payout Ratio

43.21%

P/S (TTM)

3.16

P/B

5.71

Diluted Shares

2.05B

Ex-Dividend

2026-04-02

Next Earnings

07-30

Forward P/E

9.03

Payout Ratio

86.16%

P/FCF (TTM)

9.63

FCF Yield

10.38%

Earnings Yield

5.21%

52 Week Range

Score Card

Explore Scores Tab

3.73

Good

Bristol-Myers Squibb Co has seen its revenue decline by -23.83% over the past year, which means the company is losing sales/customers. However, it has seen its operating income increase by 14.01% over the past year, which suggests its operations are becoming much more profitable.

Valuation Model

Key Score

3.00

Average

Management

5.00

Very Good

Growth

3.00

Average

Profitability

2.00

Bad

Fin. Health

4.00

Good

Dividends

2.00

Bad

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

3 new filings were in the last 7 days

Filter Form Types

Form S-8

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Filed on 2026-05-08 16:33:45

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-08 16:10:44

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 17:11:18

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-04-30 11:44:13

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-30 07:01:58

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-29 17:08:17

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-17 16:15:40

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:30:43

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:29:24

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:28:19

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:27:22

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:26:07

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$78.75

40.2%

Avg:

$63.21

12.6%

Low:

$33.43

-40.5%

(% change is relative to the current stock price: $56.16)

Analyst Recommendations

Go to Analyst Tab

3.53

Good

17%

Strong Buy (6)

25%

Buy (9)

53%

Hold (19)

Sell (2)

Strong Sell (0)

About

Website
https://www.bms.com
Address
Route 206 And Province Line Road, Princeton NEW JERSEY, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=14272

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

IPO Date

1980-03-17

Industry

Pharmaceuticals

Total Employees

32,500

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

BMY - Bristol-Myers Squibb Co

310

$56.16

-$0.09 (-0.160%)

$56.12

-$0.04 (-0.067%)

3.73/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form S-8

Filed on 2026-05-08 16:33:45

Form 8-K

Filed on 2026-05-08 16:10:44

Form 4

Filed on 2026-05-05 17:11:18

Form 10-Q

Filed on 2026-04-30 11:44:13

Form 8-K

Filed on 2026-04-30 07:01:58

Form SCHEDULE 13G

Filed on 2026-04-29 17:08:17

Form DEFA14A

Filed on 2026-04-17 16:15:40

Form 4

Filed on 2026-04-02 16:30:43

Form 4

Filed on 2026-04-02 16:29:24

Form 4

Filed on 2026-04-02 16:28:19

Form 4

Filed on 2026-04-02 16:27:22

Form 4

Filed on 2026-04-02 16:26:07

Financials

Price Targets

40.2%

12.6%

-40.5%

Analyst Recommendations

About

Similar Stocks